Shareholding disclosure

T&D - Trust Directors S.r.l

Declared position

7.78%

Threshold

Crossed upwards

Timeline

Published

31.01.2020

Transaction

23.01.2020

Transfer date

27.01.2020

Voting rights breakdown

Voting rights acquired7.78%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAK1U00063

Beneficial owner

T&D - Trust Directors S.r.l

Declared address

T&D - Trust Directors S.r.l., Milano

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

T&D - Trust Directors S.r.l

IGEA Pharma N.V.31.01.2020TAK1U00063

Disclosure summary

T&D - Trust Directors S.r.l disclosed a holding in IGEA Pharma N.V. on the acquisition side, published by SIX Exchange Regulation on 31.01.2020, at 7.78% of voting rights. Notice category: Single shareholder.

Disclosed position

7.78%

Voting rights acquired

Voting rights acquired7.78%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

T&D - Trust Directors S.r.l disclosed a holding in IGEA Pharma N.V., published on 31.01.2020.

Publication date31.01.2020

Transaction date23.01.2020

Transfer date27.01.2020

Issuing companyIGEA Pharma N.V.

Beneficial ownerT&D - Trust Directors S.r.l

Declared addressT&D - Trust Directors S.r.l., Milano

CategorySingle shareholder

Voting rights acquired7.78%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAK1U00063

Source: SIX Exchange Regulation · Publication date: 31.01.2020

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open